Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 861

1.

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM.

Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8.

PMID:
17210801
2.

Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.

Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E.

Arch Neurol. 2010 Feb;67(2):217-23. doi: 10.1001/archneurol.2009.316.

PMID:
20142530
3.

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K.

Arch Neurol. 2001 Mar;58(3):373-9.

PMID:
11255440
4.

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.

Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596.

PMID:
19273758
5.

CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.

Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ.

Neurology. 2007 Aug 14;69(7):631-9.

PMID:
17698783
6.

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.

Mol Psychiatry. 2004 Jul;9(7):705-10.

PMID:
14699432
7.

Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.

Maccioni RB, Lavados M, Guillón M, Mujica C, Bosch R, Farías G, Fuentes P.

Neurobiol Aging. 2006 Feb;27(2):237-44. Epub 2005 Apr 7.

PMID:
16399209
8.

Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.

Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.

Biol Psychiatry. 2004 Nov 1;56(9):670-6.

PMID:
15522251
9.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
10.

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A.

Arch Neurol. 2002 Nov;59(11):1729-34.

PMID:
12433260
11.

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P.

Arch Neurol. 1998 Jul;55(7):937-45.

PMID:
9678311
12.

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW Jr, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ.

Arch Neurol. 2003 Dec;60(12):1696-702.

PMID:
14676043
13.

CSF biomarkers predict rate of cognitive decline in Alzheimer disease.

Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM.

Neurology. 2009 Oct 27;73(17):1353-8. doi: 10.1212/WNL.0b013e3181bd8271.

PMID:
19858456
14.

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM.

Ann Neurol. 2006 Mar;59(3):512-9.

PMID:
16372280
15.

Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.

Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S.

Neurobiol Aging. 2009 Feb;30(2):165-73. Epub 2007 Jul 23.

PMID:
17646035
16.

CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.

Herukka SK, Hallikainen M, Soininen H, Pirttilä T.

Neurology. 2005 Apr 12;64(7):1294-7.

PMID:
15824371
17.

CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.

Bouwman FH, Schoonenboom SN, van der Flier WM, van Elk EJ, Kok A, Barkhof F, Blankenstein MA, Scheltens P.

Neurobiol Aging. 2007 Jul;28(7):1070-4. Epub 2006 Jun 19.

PMID:
16782233
18.

Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.

Höglund K, Hansson O, Buchhave P, Zetterberg H, Lewczuk P, Londos E, Blennow K, Minthon L, Wiltfang J.

Neurodegener Dis. 2008;5(5):268-76. doi: 10.1159/000119457. Epub 2008 Feb 29.

PMID:
18309230
19.

CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.

van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM.

Neurology. 2009 Mar 24;72(12):1056-61. doi: 10.1212/01.wnl.0000345014.48839.71.

PMID:
19307538
20.

Supplemental Content

Support Center